Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

DuPont strikes back at Peltz as proxy war heats up

Published 17/02/2015, 18:06
© Reuters. A view of the Dupont logo on a sign at the Dupont  Chestnut Run Plaza  facility near Wilmington, Delaware

By Swetha Gopinath

(Reuters) - DuPont (N:DD) hit back at activist investor Nelson Peltz's criticism of the company's performance, pointing out that its shareholder returns have been better than that of its rivals.

Trian, which owns a 2.68 percent stake in DuPont, has urged shareholders to vote Peltz and three other nominees to the company's board, calling the proxy vote a "referendum on DuPont's financial performance."

Up to Friday's close, DuPont's shares had risen 18 percent in the last 12 months, compared with a 7 percent increase for Dow Chemical Co (N:DOW). The S&P 500 Index (SPX) had climbed 14 percent during the period.

Dow Chemical averted a proxy fight with Dan Loeb's hedge fund, Third Point LLC, last November by agreeing to add four independent directors to its board.

Trian, which had previously called for a break-up of DuPont, said last week it was "open-minded" about keeping the company together.

DuPont said on Tuesday it had met with Trian more than 20 times in an effort to "work constructively" with the fund.

"Despite our engagement, they presented an ultimatum to DuPont that they have continued to reiterate to us – break up the company, put Trian on the DuPont board, or face a proxy fight," Chief Executive Ellen Kullman said in a letter to shareholders.

DuPont named two of its own nominees as directors earlier this month, rebuffing Peltz's demand for a board seat.

The company has also refused Trian's demand to split its materials businesses from its agriculture, nutrition and health, and industrial biosciences divisions.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

DuPont said it had started the process to spin off its performance chemicals unit "well before" Trian's investment, criticizing the hedge fund for trying to take credit for the move.

The company's board has always been willing to listen to Trian's suggestions but with Peltz insisting on a board seat for himself, a proxy fight was inevitable, a source close to DuPont told Reuters on Tuesday.

DuPont has not set a date for its annual shareholder meeting.

(Additional reporting By Kanika Sikka in Bengaluru; Editing by Saumyadeb Chakrabarty)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.